The EULAR guidelines for the management and vaccination of patients with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 advise that if a patient on long-term glucocorticoid therapy develops suspected or confirmed COVID-19, this treatment should be continued. On the other hand, patients on rituximab should consider postponing the next cycle of treatment.
In general, whether and for how long to hold antirheumatic medications for vaccination remains to be determined for some classes. Recommendations from the American College of Rheumatology have advised holding methotrexate, JAKi, abatacept, and rituximab, and later, MMF, in selected patients with controlled disease.
In addition, this patient should be advised to receive a COVID-19 vaccination in 2-3 months' time once active infections resolve.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Enrico Brunetti. Skill Checkup: A 68-Year-Old Woman With Low-Grade Fever, Headache, Body Aches, Fatigue, Nasal Congestion, and Sore Throat - Medscape - Nov 07, 2022.